Brussels, Belgium

Pierre Nokin

This inventor holds 1 USPTO granted patent. Top assignee: S. a. Labaz-Sanofi N.v.. Active years: 1983.


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 1983

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Pierre Nokin: Innovator in Therapeutics

Introduction

Pierre Nokin is a notable inventor based in Brussels, Belgium. He has made significant contributions to the field of therapeutics through his innovative research and development. His work primarily focuses on the creation of indolizine derivatives, which have potential applications in treating various physiological disturbances.

Latest Patents

Pierre Nokin holds a patent for "Indolizine derivatives and uses in therapeutics." This patent describes indolizine derivatives represented by a specific general formula. These compounds possess an inhibitory activity with respect to the action of xanthine oxidase and adenosine deaminase. They also exhibit uricosuric action, making them useful in treating conditions related to excess uric acid, disorders of the immunization system, and as antiparasitic agents. He has 1 patent to his name.

Career Highlights

Pierre Nokin is associated with S.A. Labaz-Sanofi N.V., where he continues to advance his research in the field of therapeutics. His work has garnered attention for its potential impact on medical treatments and patient care.

Collaborations

Pierre has collaborated with Gilbert Rosseels, contributing to the development of innovative therapeutic solutions. Their partnership has been instrumental in advancing their research initiatives.

Conclusion

Pierre Nokin's contributions to the field of therapeutics through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…